The global plasma protein therapeutics market size is expected to reach USD 33.15 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 4.8% over the forecast period. The growth can be attributed to high prevalence of bleeding and other rare disorders, rising investment in R&D, and increasing use of plasma-derived products in neurology and other therapeutic indications.
Plasma-derived
proteins are primarily used as replacement therapies to treat chronic, rare
diseases. Patients that rely on these medications require regular injections or
infusions throughout their lives. While there are more than 250 products
derived from plasma, key players generally rely on Immunoglobulin (IG),
albumin, and factor VIII to drive sales and profitability.
Over
the past decade, the plasma protein therapeutics market has grown lucratively
with immunoglobulin capturing the major market share. Demand for plasma
derived-products is driven by rising disease prevalence, geriatric population,
and improved access to drugs in emerging markets. Approvals of new
plasma-derived therapies are anticipated to further fuel the demand. Developing
countries such as China and Brazil offer new investment avenues to the global
market giants.
For Full Research Report On Plasma Protein Therapeutic Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/plasma-protein-therapeutic
Further key
findings from the report suggest:
- Germany leads the European
market, supported by high demand for blood components, presence of key
players, large addressable population, and rising disease prevalence
- Demand for immunoglobulin is
expected to continue rising owing to prevalence of primary
immunodeficiencies, usage in new indications, and ease of administration
- Non-plasma based recombinant
therapies are likely to compete with plasma-derived products in the factor
VIII market
- Asia Pacific is expected to
exhibit high growth over the forecast period fueled by increasing
healthcare expenditure, presence of a large number patients. improved
ratio of patients suffering from disease and patients receiving treatment,
low-cost production of drugs, and improvement in diagnostic technology.
- Major players operating in
the plasma protein therapeutics market include CSL Behring, Grifols, S.A.,
Shire Plc, Octapharma AG, Biotest AG, and Kedrion S.P.A. Regional
expansion, broad product portfolio, and merger & acquisitions are
chief strategic undertakings adopted by key players.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/plasma-protein-therapeutic/request/rs1
Grand View Research has segmented
the global plasma protein therapeutics market on the basis of product,
application, and region:
Plasma Proteins
Therapeutics Product Outlook (Revenue, USD Million, 2014 - 2025)
- Albumin
- Immunoglobulin
- Factor VIII
Plasma Proteins
Therapeutics Application Outlook (Revenue, USD Million, 2014 - 2025)
- Hemophilia
- Primary Immunodeficiency
Disorder (PID)
- Idiopathic Thrombocytopenic
Purpura (ITP)
- Others
Plasma Protein
Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Mexico
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment